Avadel is now a deal story
- Avadel sells LUMRYZ, a once-at-bedtime sodium oxybate medicine for narcolepsy.
- The internal thesis now centers on Alkermes buying Avadel for $18.50 per share plus a CVR of up to $1.50.
- Jazz litigation was settled on October 21, 2025, removing a major legal overhang.
- LUMRYZ generated $68.1 million of net product revenue in the quarter ended June 30, 2025.
- The key risk is no longer only drug sales. It is whether the Alkermes transaction closes on the expected terms.
The buyout is the main event
Avadel used to be a pure LUMRYZ growth story. The internal thesis changed after Avadel announced a definitive agreement on October 22, 2025 for Alkermes to acquire the company for $18.50 per share in cash plus a contingent value right, or CVR, of up to $1.50 per share. A CVR is an extra payment that depends on future targets being met.
The bull case is simple. The deal closes on the agreed terms, and holders receive the cash price plus any future CVR value if the milestones are met. The October 21, 2025 settlement with Jazz Pharmaceuticals helps that case because it removed a major legal fight over LUMRYZ.
The bear case is deal failure or a long delay. If shareholders, regulators, a court process, or a material business problem block the transaction, the stock would likely be judged again as a standalone single-product biotech. That would bring back the normal risks around funding, competition, and execution.
There is also a timing tension. The internal file frames the deal as pending and expected to close in Q1 2026, while later public transaction records may update that status. A reader should check the latest trading and closing notices before treating AVDL as a live standalone stock.
One drug, one buyer
Avadel makes money from LUMRYZ. It is an extended-release version of sodium oxybate used to treat cataplexy or excessive daytime sleepiness in narcolepsy. The main selling point is once-at-bedtime dosing, which avoids a middle-of-the-night second dose.
For the quarter ended June 30, 2025, Avadel reported $68.1 million in LUMRYZ net product revenue. The company said all reported net product revenue came from this product, so the business is highly concentrated.
Before the deal announcement, the story was about whether LUMRYZ could keep adding patients and move Avadel into steady profit. In Q2 2025, Avadel reported its first net income since launch, nearly $10 million, and raised full-year 2025 revenue guidance to $265 million to $275 million.
After the deal announcement, the business still matters, but mainly as support for the transaction. Strong LUMRYZ trends make it less likely that the buyer walks away, while a sudden sales slowdown could raise deal and valuation questions.
The sleep portfolio
LUMRYZ adult narcolepsy
This is Avadel's commercial product and the source of reported product revenue. It treats cataplexy or excessive daytime sleepiness in adults with narcolepsy.
LUMRYZ pediatric narcolepsy
The FDA approved LUMRYZ for patients seven years and older on October 16, 2024. This expands the addressable narcolepsy population beyond adults.
LUMRYZ idiopathic hypersomnia
Avadel is testing LUMRYZ in idiopathic hypersomnia through the Phase 3 REVITALYZ trial. Management expected enrollment to complete by the end of 2025, with data in 2026 and a possible supplemental NDA filing in the second half of 2026.
Valiloxybate
On August 30, 2025, Avadel licensed global rights from XWPharma for valiloxybate, a GABAB receptor agonist. The target areas include narcolepsy and idiopathic hypersomnia.
All revenue points to LUMRYZ
Avadel reports as a single business focused on LUMRYZ. The mix shown uses the latest internal segment view and Q2 2025 disclosure: all reported net product revenue came from LUMRYZ, with no current revenue from pipeline or license assets.
What could break the story
Deal closing risk
High impact · Medium oddsThe biggest risk is that the Alkermes transaction fails or takes longer than expected. The company itself warned that failure to complete, or delays in completing, the pending transaction could hurt results and the share price.
CVR uncertainty
Medium impact · Medium oddsThe deal includes a CVR of up to $1.50 per share, but the internal thesis still flags the milestones and timing as an open question. If the targets are hard to hit or take years, the CVR may be worth much less than its headline amount.
Single-product exposure
High impact · Medium oddsAvadel depends on LUMRYZ for reported product revenue. If prescriptions slow, payers push back, safety issues appear, or patients switch away, the standalone business would have little revenue diversity.
Competition in oxybates
Medium impact · Medium oddsLUMRYZ competes in a market that includes other sodium oxybate products, generics, and new sleep-disorder drug classes. Its once-at-bedtime dosing helps, but rivals can still pressure price, share, or doctor habits.
Post-filing status gap
Medium impact · Medium oddsThe internal thesis still treats the Alkermes deal as pending, with expected closing in Q1 2026. Because this page is run after that window, public transaction records may have changed the practical status of AVDL as a tradable standalone company.
In one breath
What does Avadel Pharmaceuticals do?
Avadel sells LUMRYZ, a once-at-bedtime sodium oxybate medicine for narcolepsy. Its main value driver is now the agreed Alkermes acquisition rather than only future LUMRYZ growth.
What is the Alkermes deal for Avadel?
The internal thesis says Alkermes agreed to buy Avadel for $18.50 per share in cash plus a CVR of up to $1.50 per share. The deal was expected to close in Q1 2026, subject to customary closing conditions.
Why did the Jazz settlement matter?
Jazz had been a major legal overhang for Avadel. The October 21, 2025 settlement resolved the outstanding litigation and likely made the Alkermes transaction easier to complete.
What should investors watch now?
The most important items are the deal closing status, the CVR terms, and any public filing that changes whether AVDL still trades as a standalone stock. If the deal does not close, LUMRYZ sales trends become the core value driver again.